Pub Date : 2024-03-15DOI: 10.1186/s43045-024-00409-6
Eman Ibrahim Abo El Ella, Eman S. Rabie, Mona Mahmoud El Sheikh, Reem Hassan El Ghamry, Mostafa Salah Hotar, Fiby Fayez Gabrielle
Inflammation has been demonstrated to play a pathophysiological function in schizophrenia. Raised interleukin-6 (IL-6) levels have been the most consistently linked to schizophrenia. It was hypothesized that IL-6 contributed to the development of both adverse and beneficial symptoms. The aim of the study was to estimate the level of serum IL-6 in patients with schizophrenia and its relation to positive in addition to negative symptoms. This case–control descriptive cross-sectional study was conducted on 40 patients, divided into two groups: 20 individuals in Group A (patients group) were treatment-naive for their first episode of schizophrenia, and 20 volunteers in Group B (control group) were matched for gender and age to the patient group. Both groups were evaluated for their serum interleukin-6 levels using the ELISA method. Patients and controls were recruited from the Okasha Institute of Psychiatry, Faculty of Medicine, and Ain Shams University Hospitals. Cases with schizophrenia who were experiencing their first episode and had not yet begun any form of therapy had a considerably higher mean serum IL-6 level compared to the healthy control group. The level of serum interleukin 6 in first-episode treatment-naïve individuals with schizophrenia is higher than that of healthy controls, revealing a probable underlying immunological pathology. However, serum interleukin-6 levels were not significantly correlated with positive, negative, or general psychopathology symptoms.
{"title":"Assessment of serum interleukin 6 in a sample of Egyptian patients with schizophrenia","authors":"Eman Ibrahim Abo El Ella, Eman S. Rabie, Mona Mahmoud El Sheikh, Reem Hassan El Ghamry, Mostafa Salah Hotar, Fiby Fayez Gabrielle","doi":"10.1186/s43045-024-00409-6","DOIUrl":"https://doi.org/10.1186/s43045-024-00409-6","url":null,"abstract":"Inflammation has been demonstrated to play a pathophysiological function in schizophrenia. Raised interleukin-6 (IL-6) levels have been the most consistently linked to schizophrenia. It was hypothesized that IL-6 contributed to the development of both adverse and beneficial symptoms. The aim of the study was to estimate the level of serum IL-6 in patients with schizophrenia and its relation to positive in addition to negative symptoms. This case–control descriptive cross-sectional study was conducted on 40 patients, divided into two groups: 20 individuals in Group A (patients group) were treatment-naive for their first episode of schizophrenia, and 20 volunteers in Group B (control group) were matched for gender and age to the patient group. Both groups were evaluated for their serum interleukin-6 levels using the ELISA method. Patients and controls were recruited from the Okasha Institute of Psychiatry, Faculty of Medicine, and Ain Shams University Hospitals. Cases with schizophrenia who were experiencing their first episode and had not yet begun any form of therapy had a considerably higher mean serum IL-6 level compared to the healthy control group. The level of serum interleukin 6 in first-episode treatment-naïve individuals with schizophrenia is higher than that of healthy controls, revealing a probable underlying immunological pathology. However, serum interleukin-6 levels were not significantly correlated with positive, negative, or general psychopathology symptoms.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140148952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The existing body of literature extensively highlights the impact of psychological determinants on the initiation of coronary heart disease. Globally, the incidence of psychiatric disorders is increasing, and India is no stranger to this trend. However, the connection between psychiatric co-morbidities and the onset of acute coronary syndrome has been relatively understudied in this region of the world. Individuals experiencing acute coronary syndrome exhibited notably higher psychiatric morbidity compared to the control group, with an odds ratio of 4.14. Mood disorders, in particular, were the most prevalent among ACS patients, demonstrating an odds ratio of 5.023, followed by anxiety disorders with an odds ratio of 2.48. The findings revealed a substantial association underscoring the intricate interplay between mental and cardiovascular health emphasizing the importance of holistic healthcare approaches that consider both physical and psychological well-being, in the context of cardiovascular diseases. Further research in this area can contribute to a more comprehensive understanding of the links between mental health and cardiovascular outcomes, potentially informing targeted interventions and improving overall patient care.
{"title":"Prevalence and pattern of psychiatric morbidity in patients with first-episode acute coronary syndrome","authors":"Nighat Akbar, Kubra Farooq, Neelofar Jan, Marya Zahoor, Yasir Hassan Rather, Ubaid Rasool Bhat","doi":"10.1186/s43045-024-00408-7","DOIUrl":"https://doi.org/10.1186/s43045-024-00408-7","url":null,"abstract":"The existing body of literature extensively highlights the impact of psychological determinants on the initiation of coronary heart disease. Globally, the incidence of psychiatric disorders is increasing, and India is no stranger to this trend. However, the connection between psychiatric co-morbidities and the onset of acute coronary syndrome has been relatively understudied in this region of the world. Individuals experiencing acute coronary syndrome exhibited notably higher psychiatric morbidity compared to the control group, with an odds ratio of 4.14. Mood disorders, in particular, were the most prevalent among ACS patients, demonstrating an odds ratio of 5.023, followed by anxiety disorders with an odds ratio of 2.48. The findings revealed a substantial association underscoring the intricate interplay between mental and cardiovascular health emphasizing the importance of holistic healthcare approaches that consider both physical and psychological well-being, in the context of cardiovascular diseases. Further research in this area can contribute to a more comprehensive understanding of the links between mental health and cardiovascular outcomes, potentially informing targeted interventions and improving overall patient care.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140099611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-08DOI: 10.1186/s43045-024-00403-y
Salwa Amin Abd Elhamid, Mohammad Mostafa Alkherkhisy, Rania Elsayed Kasem
The autism spectrum disorder (ASD) has no identified biomarker for early detection or for its severity. As for the brain-derived neurotrophic factor (BDNF), it is a crucial neurotropic factor that regulates the plasticity and maturing of neuronal synapses. Accordingly, it might influence how children with autism develop. To evaluate the BDNF serum levels in autistic children and their relationship with the illness severity as well as with the common drugs received by autistic patients, 60 patients with autism along with another 60 normally developing children were involved in the study. Using the Childhood Autism Rating Scale (CARS), the severity of autism was then evaluated. The ELISA method was used to measure the BDNF level. It was seen that the BDNF concentrations were higher in autism patients (P < 0.001). There was also a highly strong positive association between the CARS score and the BDNF (P < 0.001). Using the cut-off value of > 2.8 of BDNF helped to distinguish between well-developing and autistic children, with the aspects of “sensitivity” and “specificity” being 88.3% and 80%, respectively. Moreover, children with autism who received omega-3 had statistically lower levels of BDNF than those who did not take any (P = 0.040). The serum BDNF concentration is higher in autism; this proposes that the BDNF may contribute to the onset or progress of autism. Therefore, it may be used as a noninvasive biomarker for the illness severity because of its greater occurrence in autistic children who have severe social impairment.
{"title":"Assessment of brain-derived neurotrophic factor levels in serum of children with autism spectrum disorders","authors":"Salwa Amin Abd Elhamid, Mohammad Mostafa Alkherkhisy, Rania Elsayed Kasem","doi":"10.1186/s43045-024-00403-y","DOIUrl":"https://doi.org/10.1186/s43045-024-00403-y","url":null,"abstract":"The autism spectrum disorder (ASD) has no identified biomarker for early detection or for its severity. As for the brain-derived neurotrophic factor (BDNF), it is a crucial neurotropic factor that regulates the plasticity and maturing of neuronal synapses. Accordingly, it might influence how children with autism develop. To evaluate the BDNF serum levels in autistic children and their relationship with the illness severity as well as with the common drugs received by autistic patients, 60 patients with autism along with another 60 normally developing children were involved in the study. Using the Childhood Autism Rating Scale (CARS), the severity of autism was then evaluated. The ELISA method was used to measure the BDNF level. It was seen that the BDNF concentrations were higher in autism patients (P < 0.001). There was also a highly strong positive association between the CARS score and the BDNF (P < 0.001). Using the cut-off value of > 2.8 of BDNF helped to distinguish between well-developing and autistic children, with the aspects of “sensitivity” and “specificity” being 88.3% and 80%, respectively. Moreover, children with autism who received omega-3 had statistically lower levels of BDNF than those who did not take any (P = 0.040). The serum BDNF concentration is higher in autism; this proposes that the BDNF may contribute to the onset or progress of autism. Therefore, it may be used as a noninvasive biomarker for the illness severity because of its greater occurrence in autistic children who have severe social impairment.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140072914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.1186/s43045-024-00402-z
M. Farouk, M. Nasr, M. Khalil, I. Dozebik, S. El Makawi, W. Fakher, D. R. Ayoub
Comorbid personality disorders and obsessive–compulsive disorder (OCD) range between 33 and 87%. Patients having OCD more commonly receive cluster A (the odd and eccentric cluster) compared with other nonpsychotic patients. Poor insight levels within OCD increase disease severity and impair neuropsychological factors, where OCD patients exhibit poorer speech learning and memory. To assess schizotypal, autistic traits, and insight levels in patients with OCD. Forty subjects with OCD were recruited from outpatient clinics of Kasr Alainy Psychiatry and Addiction Prevention Hospital and assessed using the Dimensional Yale-Brown Obsessive–Compulsive Scale (DYBOCS), Schizotypal Personality Questionnaire-Brief Revised (SPQ-BR), and Autism Spectrum Quotient (AQ) while insight level was assessed using Brown Assessment of Beliefs Scale (BABS). Total DY-BOCS score was positively correlated with the AQ score and SPQ score. Global distress and interference subdomains of DY-BOCS were positively correlated with AQ, SPQ score, and Insight level (BABS). Indicating that the worse the insight the higher the distress and interference in daily life. Global distress and interference were also positively correlated to all subscales of SPQ. Aggressive obsessions were correlated with SPQ score, cognitive-perceptual (CP) traits, ideas of reference, and magical thinking. Contamination/cleaning obsessions were positively correlated with the level of insight (BABS). While sexual and religious obsessions were negatively correlated with the level of insight. Increased severity of OCD is associated with more autistic symptoms, schizotypal symptoms, and poorer insight. No gender differences in OCD patients regarding severity, autistic symptoms, schizotypal symptoms, or insight.
{"title":"Autistic, schizotypal traits, and insight level in patients with obsessive–compulsive disorder","authors":"M. Farouk, M. Nasr, M. Khalil, I. Dozebik, S. El Makawi, W. Fakher, D. R. Ayoub","doi":"10.1186/s43045-024-00402-z","DOIUrl":"https://doi.org/10.1186/s43045-024-00402-z","url":null,"abstract":"Comorbid personality disorders and obsessive–compulsive disorder (OCD) range between 33 and 87%. Patients having OCD more commonly receive cluster A (the odd and eccentric cluster) compared with other nonpsychotic patients. Poor insight levels within OCD increase disease severity and impair neuropsychological factors, where OCD patients exhibit poorer speech learning and memory. To assess schizotypal, autistic traits, and insight levels in patients with OCD. Forty subjects with OCD were recruited from outpatient clinics of Kasr Alainy Psychiatry and Addiction Prevention Hospital and assessed using the Dimensional Yale-Brown Obsessive–Compulsive Scale (DYBOCS), Schizotypal Personality Questionnaire-Brief Revised (SPQ-BR), and Autism Spectrum Quotient (AQ) while insight level was assessed using Brown Assessment of Beliefs Scale (BABS). Total DY-BOCS score was positively correlated with the AQ score and SPQ score. Global distress and interference subdomains of DY-BOCS were positively correlated with AQ, SPQ score, and Insight level (BABS). Indicating that the worse the insight the higher the distress and interference in daily life. Global distress and interference were also positively correlated to all subscales of SPQ. Aggressive obsessions were correlated with SPQ score, cognitive-perceptual (CP) traits, ideas of reference, and magical thinking. Contamination/cleaning obsessions were positively correlated with the level of insight (BABS). While sexual and religious obsessions were negatively correlated with the level of insight. Increased severity of OCD is associated with more autistic symptoms, schizotypal symptoms, and poorer insight. No gender differences in OCD patients regarding severity, autistic symptoms, schizotypal symptoms, or insight.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140025506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recall bias of patients and their relatives, low reliability of the history, changes in attention deficit hyperactivity disorder (ADHD) symptoms or compensatory behaviors, and various comorbidities may be associated with difficulties in diagnosing ADHD in adults. Barkley Adult Attention Deficit Hyperactivity Disorder Rating Scale-IV (BAARS-IV), a relatively new scale, needs to be studied for validity and reliability in different societies and cultures. In this study, we investigated whether the Turkish version of BAARS-IV: Present Symptoms Section is valid and reliable in the medical students who constituted the sample. Adult Attention Deficit Hyperactivity Disorder Self-Report Scale and BAARS-IV: Present Symptoms Section were administered to 402 fifth- and sixth-year medical students. We performed exploratory and confirmatory factor analyzes. Cronbach’s alpha and inter-item correlation were evaluated. Pearson correlation test was used in inter-scale correlation analyses. For ADHD items, Kaiser-Meyer-Olkin (KMO) (0.882), Measuring of Sampling Adequacy MSA (0.819), chi-square (2512.455), and p (< 0.001) values showed that the data were suitable for factor analysis. A three-factor structure with an eigenvalue above 1 and explaining 53.14% of the total variance was obtained. In the correlation matrix reconstructed with eight Sluggish Cognitive Tempo (SCT) items, the determinant of the correlation matrix was 0.025, the KMO determinant was 0.852, the lowest MSA value was 0.750, and the residual rate was 14%. A two-factor structure was obtained explaining 67.451% of the variance. Cronbach’s alpha values of the inattention and impulsivity subscales were 0.839 and 0.752, respectively. Cronbach’s alpha value of 8 questions in the SCT scale was found to be 0.871. The results of our study indicate that the BAARS-IV Self-report Present Symptoms scale is valid and reliable among medical students.
{"title":"Turkish reliability and validity study of Barkley’s BAARS-IV self-report current symptoms","authors":"Tansu Eda Topaloglu, Bilge Dogan, Doga Sevincok, Levent Sevincok","doi":"10.1186/s43045-024-00406-9","DOIUrl":"https://doi.org/10.1186/s43045-024-00406-9","url":null,"abstract":"Recall bias of patients and their relatives, low reliability of the history, changes in attention deficit hyperactivity disorder (ADHD) symptoms or compensatory behaviors, and various comorbidities may be associated with difficulties in diagnosing ADHD in adults. Barkley Adult Attention Deficit Hyperactivity Disorder Rating Scale-IV (BAARS-IV), a relatively new scale, needs to be studied for validity and reliability in different societies and cultures. In this study, we investigated whether the Turkish version of BAARS-IV: Present Symptoms Section is valid and reliable in the medical students who constituted the sample. Adult Attention Deficit Hyperactivity Disorder Self-Report Scale and BAARS-IV: Present Symptoms Section were administered to 402 fifth- and sixth-year medical students. We performed exploratory and confirmatory factor analyzes. Cronbach’s alpha and inter-item correlation were evaluated. Pearson correlation test was used in inter-scale correlation analyses. For ADHD items, Kaiser-Meyer-Olkin (KMO) (0.882), Measuring of Sampling Adequacy MSA (0.819), chi-square (2512.455), and p (< 0.001) values showed that the data were suitable for factor analysis. A three-factor structure with an eigenvalue above 1 and explaining 53.14% of the total variance was obtained. In the correlation matrix reconstructed with eight Sluggish Cognitive Tempo (SCT) items, the determinant of the correlation matrix was 0.025, the KMO determinant was 0.852, the lowest MSA value was 0.750, and the residual rate was 14%. A two-factor structure was obtained explaining 67.451% of the variance. Cronbach’s alpha values of the inattention and impulsivity subscales were 0.839 and 0.752, respectively. Cronbach’s alpha value of 8 questions in the SCT scale was found to be 0.871. The results of our study indicate that the BAARS-IV Self-report Present Symptoms scale is valid and reliable among medical students.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139969001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-23DOI: 10.1186/s43045-024-00407-8
Fadia Zyada, Hala Hamdy, N. El Basha, Mohamed Refaey, Fatma M. Atia, Somaya H. Shaheen
Even though current therapeutic approaches have significantly increased the longevity and standard of living for children suffering from cystic fibrosis (CF), the crucial psychological components of this illness have not received the same level of attention as other chronic illnesses. The aim of the research was to assess depression, anxiety, and hopelessness in cystic fibrosis-affected children and their relation to the duration of illness. In this study, we compared 40 healthy control children between the ages of 7 and 12 with 40 cystic fibrosis children who were matched for age and sex. All patients had detailed clinical and psychometric evaluations using the Children’s Depression Inventory (CDI), the Anxiety Scale for Children (ASC), and the Hopelessness Scale for Children (HSC). The CDI, ASC, and HSC revealed a significant difference between both groups. Positive correlations between depression, anxiety, and hopelessness and disease duration were found. Patients with CF experienced significantly increased depression, anxiety, and hopelessness, and there is an association between these symptoms and the duration of the illness. We advise making psychiatric screening a standard part of evaluating and monitoring CF patients.
{"title":"Depression, anxiety, and hopelessness in a sample of Egyptian children diagnosed with cystic fibrosis","authors":"Fadia Zyada, Hala Hamdy, N. El Basha, Mohamed Refaey, Fatma M. Atia, Somaya H. Shaheen","doi":"10.1186/s43045-024-00407-8","DOIUrl":"https://doi.org/10.1186/s43045-024-00407-8","url":null,"abstract":"Even though current therapeutic approaches have significantly increased the longevity and standard of living for children suffering from cystic fibrosis (CF), the crucial psychological components of this illness have not received the same level of attention as other chronic illnesses. The aim of the research was to assess depression, anxiety, and hopelessness in cystic fibrosis-affected children and their relation to the duration of illness. In this study, we compared 40 healthy control children between the ages of 7 and 12 with 40 cystic fibrosis children who were matched for age and sex. All patients had detailed clinical and psychometric evaluations using the Children’s Depression Inventory (CDI), the Anxiety Scale for Children (ASC), and the Hopelessness Scale for Children (HSC). The CDI, ASC, and HSC revealed a significant difference between both groups. Positive correlations between depression, anxiety, and hopelessness and disease duration were found. Patients with CF experienced significantly increased depression, anxiety, and hopelessness, and there is an association between these symptoms and the duration of the illness. We advise making psychiatric screening a standard part of evaluating and monitoring CF patients.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139954307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Research on dysmorphic concerns (DC) in Arabic-speaking contexts is hampered by the lack of validated tools. Because DC are culturally dependent, psychometrically sound measures are needed at the national level to closely and accurately investigate the construct in specific societies and populations. The purpose of the current research was to investigate the psychometric properties of Dysmorphic Concern Questionnaire (DCQ) in its Arabic translation in Lebanese adults. The study involved 515 participants (69.9% females, mean age of 27.55 ± 10.92 years) who completed a self-report, web-based questionnaire. Confirmatory factor analysis indicated excellent construct validity, as the one-factor structure of the Arabic DCQ fits well with the data. McDonald’s omega was 0.89 in our sample, evidencing an excellent level of internal consistency. Furthermore, the results from the multigroup analysis showed that the DCQ holds similar structural model between genders at the metric, configural, and scalar levels. Finally, DC levels correlated inversely with body appreciation and self-esteem and positively with disordered eating symptoms, thus supporting the concurrent and convergent validity of the Arabic DCQ. The DCQ translated into Arabic appears to have a valid self-assessment measure to capture the presence of DC manifestations. It is anticipated that the Arabic DCQ will be advantageous for healthcare professionals and researchers working with Arabic-speaking people around the world.
{"title":"Psychometric validation of the Dysmorphic Concern Questionnaire (DCQ) into Arabic","authors":"Feten Fekih-Romdhane, Rabih Hallit, Vanessa Azzi, Diana Malaeb, Fouad Sakr, Mariam Dabbous, Tabassum Rashid, Toni Sawma, Sahar Obeid, Souheil Hallit","doi":"10.1186/s43045-024-00401-0","DOIUrl":"https://doi.org/10.1186/s43045-024-00401-0","url":null,"abstract":"Research on dysmorphic concerns (DC) in Arabic-speaking contexts is hampered by the lack of validated tools. Because DC are culturally dependent, psychometrically sound measures are needed at the national level to closely and accurately investigate the construct in specific societies and populations. The purpose of the current research was to investigate the psychometric properties of Dysmorphic Concern Questionnaire (DCQ) in its Arabic translation in Lebanese adults. The study involved 515 participants (69.9% females, mean age of 27.55 ± 10.92 years) who completed a self-report, web-based questionnaire. Confirmatory factor analysis indicated excellent construct validity, as the one-factor structure of the Arabic DCQ fits well with the data. McDonald’s omega was 0.89 in our sample, evidencing an excellent level of internal consistency. Furthermore, the results from the multigroup analysis showed that the DCQ holds similar structural model between genders at the metric, configural, and scalar levels. Finally, DC levels correlated inversely with body appreciation and self-esteem and positively with disordered eating symptoms, thus supporting the concurrent and convergent validity of the Arabic DCQ. The DCQ translated into Arabic appears to have a valid self-assessment measure to capture the presence of DC manifestations. It is anticipated that the Arabic DCQ will be advantageous for healthcare professionals and researchers working with Arabic-speaking people around the world.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139927411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-15DOI: 10.1186/s43045-024-00405-w
Ramin Abdi Dezfouli, Sara Akbariforoud, Ensieh Esmaeilidezfouli
To assess the effectiveness, safety, and tolerability of anti-Alzheimer agents (memantine, galantamine, rivastigmine, and donepezil) in controlling ADHD symptoms in children, adolescents, and adults. Following the PRISMA guideline, clinical trials assessing the potency of anti-Alzheimer medications in managing ADHD symptoms were imported from PubMed, Web of Science, and Scopus (until February 2023). Screening stages were conducted by two independent researchers. Two independent researchers also extracted data from clinical trials reporting the outcomes as the reduction in scores of ADHD questionnaires. The risk of bias within the included studies was assessed using the Cochrane Collaboration tool, while the certainty of outcomes was evaluated based on the GRADE criteria. Of the initial 1597 studies, 11 studies were included. No studies were available for rivastigmine, and only a single study was conducted for galantamine. The results of the other two medications had a slight inconsistency. While both memantine and donepezil were reported to be effective in several studies, they were reported to be ineffective in some other studies. Side effects were mostly reduced appetite and headache. The tolerability of memantine, donepezil, and galantamine was all convincing. While galantamine did not demonstrate a promising efficacy in ADHD, memantine and donepezil showed effectiveness. However, future studies are needed to confirm their efficacy in ADHD since there was some inconsistency.
{"title":"Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review","authors":"Ramin Abdi Dezfouli, Sara Akbariforoud, Ensieh Esmaeilidezfouli","doi":"10.1186/s43045-024-00405-w","DOIUrl":"https://doi.org/10.1186/s43045-024-00405-w","url":null,"abstract":"To assess the effectiveness, safety, and tolerability of anti-Alzheimer agents (memantine, galantamine, rivastigmine, and donepezil) in controlling ADHD symptoms in children, adolescents, and adults. Following the PRISMA guideline, clinical trials assessing the potency of anti-Alzheimer medications in managing ADHD symptoms were imported from PubMed, Web of Science, and Scopus (until February 2023). Screening stages were conducted by two independent researchers. Two independent researchers also extracted data from clinical trials reporting the outcomes as the reduction in scores of ADHD questionnaires. The risk of bias within the included studies was assessed using the Cochrane Collaboration tool, while the certainty of outcomes was evaluated based on the GRADE criteria. Of the initial 1597 studies, 11 studies were included. No studies were available for rivastigmine, and only a single study was conducted for galantamine. The results of the other two medications had a slight inconsistency. While both memantine and donepezil were reported to be effective in several studies, they were reported to be ineffective in some other studies. Side effects were mostly reduced appetite and headache. The tolerability of memantine, donepezil, and galantamine was all convincing. While galantamine did not demonstrate a promising efficacy in ADHD, memantine and donepezil showed effectiveness. However, future studies are needed to confirm their efficacy in ADHD since there was some inconsistency.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"126 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139765431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-12DOI: 10.1186/s43045-024-00404-x
Mohammad Tahan, Gholamali Afrooz, Jafar Bolhari
This study aimed to evaluate the effect of a robot-based psychological intervention on the prevention of inappropriate touching of children. The trial was registered in the International Clinical Trial Registry Platform with the registration id of ISRCTN17186302. In this study, the intervention had a positive effect on inappropriate sexual care in elementary school children (P < 0.01). Moreover, education on sexual care heightened children’s knowledge about inappropriate touch (P < 0.01). According to the results, the robot-based psychological intervention had an impact on children’s sexual care. It is suggested that this method be applied by counselors and psychologists as a therapeutic approach.
{"title":"Training of a robot-based psychological intervention program to prevent inappropriate touching of children","authors":"Mohammad Tahan, Gholamali Afrooz, Jafar Bolhari","doi":"10.1186/s43045-024-00404-x","DOIUrl":"https://doi.org/10.1186/s43045-024-00404-x","url":null,"abstract":"This study aimed to evaluate the effect of a robot-based psychological intervention on the prevention of inappropriate touching of children. The trial was registered in the International Clinical Trial Registry Platform with the registration id of ISRCTN17186302. In this study, the intervention had a positive effect on inappropriate sexual care in elementary school children (P < 0.01). Moreover, education on sexual care heightened children’s knowledge about inappropriate touch (P < 0.01). According to the results, the robot-based psychological intervention had an impact on children’s sexual care. It is suggested that this method be applied by counselors and psychologists as a therapeutic approach.","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139765353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-09DOI: 10.1186/s43045-024-00399-5
Hadi Delpasand, Azadeh Mazaheri, Ali Kheradmand, Mahdi Ghorbani, Amir Reza Abedi, Mohsen Khosroabadi
Premature ejaculation is one of the most common male sexual dysfunction, affecting approximately 30% of men. The aim of this study is to evaluate the efficacy and at the same time the safety of the cranial electrotherapy stimulation (CES) device in treatment of premature ejaculation disorder. Based on a randomized clinical trial, two groups were included in the study, so that the first group was treated with sertraline along with an ATANG (AT-9 model) CES, and the second group with sertraline and inactive the CES device (as the placebo group). The state of premature ejaculation after treatment (using the Premature Ejaculation Diagnostic Tool (PEDT) questionnaire) was evaluated and compared for both groups. In the intervention and placebo groups, the average score of the PEDT questionnaire before the intervention did not differ significantly between the two groups (p-value equal to 0.93). However, the average score of the PEDT questionnaire after the intervention for CES group and placebo group was 10.28 ± 1.93 and 13.23 ± 3.05, respectively, which demonstrated a significant decrease in the intervention group (p-value equal to 0.01). The use of CES device as a complementary treatment along with routine drug treatment (sertraline) is associated with a significant improvement in the condition of premature ejaculation of patients. Name of the registry: IRCT Iranian Registry of Clinical Trials. Trial registration number: IRCT20210621051657N1. Date of registration: December 11, 2022. URL of trial registry record: https://en.irct.ir/trial/57201 .
{"title":"Effect of cranial electrotherapy stimulation (CES) in treatment of premature ejaculation: a randomized clinical trial","authors":"Hadi Delpasand, Azadeh Mazaheri, Ali Kheradmand, Mahdi Ghorbani, Amir Reza Abedi, Mohsen Khosroabadi","doi":"10.1186/s43045-024-00399-5","DOIUrl":"https://doi.org/10.1186/s43045-024-00399-5","url":null,"abstract":"Premature ejaculation is one of the most common male sexual dysfunction, affecting approximately 30% of men. The aim of this study is to evaluate the efficacy and at the same time the safety of the cranial electrotherapy stimulation (CES) device in treatment of premature ejaculation disorder. Based on a randomized clinical trial, two groups were included in the study, so that the first group was treated with sertraline along with an ATANG (AT-9 model) CES, and the second group with sertraline and inactive the CES device (as the placebo group). The state of premature ejaculation after treatment (using the Premature Ejaculation Diagnostic Tool (PEDT) questionnaire) was evaluated and compared for both groups. In the intervention and placebo groups, the average score of the PEDT questionnaire before the intervention did not differ significantly between the two groups (p-value equal to 0.93). However, the average score of the PEDT questionnaire after the intervention for CES group and placebo group was 10.28 ± 1.93 and 13.23 ± 3.05, respectively, which demonstrated a significant decrease in the intervention group (p-value equal to 0.01). The use of CES device as a complementary treatment along with routine drug treatment (sertraline) is associated with a significant improvement in the condition of premature ejaculation of patients. Name of the registry: IRCT Iranian Registry of Clinical Trials. Trial registration number: IRCT20210621051657N1. Date of registration: December 11, 2022. URL of trial registry record: https://en.irct.ir/trial/57201 .","PeriodicalId":38653,"journal":{"name":"Middle East Current Psychiatry","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139765429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：